Quantification of Atazanavir and Ritonavir in Human Plasma Samples by Rp- Hplc Include Method of Detection in the Title, Eg: Using Pda Detection

Abstract

A fixed oral dose combination of Atazanavir and Ritonavir is currently used for the treatment of patients with HIV infections.  A  selective  and  novel  bio-analytical  technique  was  designed  to  evaluate  Atazanavir  and  Ritonavir  by  mass spectroscopic investigation in plasma matrices. The method was chromatographed with Agilent TC-C18, 4.6 x 75 mm, 3.5 µm, 80 Å column, 5mM ammonium acetate: acetonitrile (20:80 v/v) mobile phase was used for Chromatographic separation. UV detector was used to detect the Atazanavir and Ritonavir at 235 nm. For extraction of the analyte and internal standard, Liquid-liquid extraction was employed .This method is validated over a linear concentration range of 50.0 – 10000.0 ng/ml for Atazanavir and Ritonavir with a correlation coefficient (r) of = 0.9997 and  both drugs were stable in plasma samples.